NeoStem, Inc. (NBS) Subsidiary Progenitor Cell Therapy Secures Key Brain Cancer Vaccine Manufacturing Agreement with ImmunoCellular Therapeutics
NeoStem, an extremely well-positioned leader in the cell therapy space, via wholly-owned subsidiary Progenitor Cell Therapy, LLC, recently announced a major manufacturing agreement with clinical-stage biotech firm ImmunoCellular Therapeutics, Ltd., a developer of innovative immune-based therapies for brain and other cancers. Progenitor will serve a key manufacturing role in production during the run up to Phase II clinical trials of ICT-107, obtaining a strong foothold for as a strategic partner for a future Phase III involving the powerful new glioblastoma vaccine, which utilizes a dendritic cell-based targeting of a host of antigens linked to such tumors. President and CSO of…